The Three Dimensional Thirring Model for Small N_f

We formulate the three dimensional Thirring model on a spacetime lattice and study it for various even numbers of fermion flavors N_f by Monte Carlo simulation. We find clear evidence for spontaneous chiral symmetry breaking at strong coupling, contradicting the predictions of the 1/N_f expansion. The critical point appears to correspond to an ultra-violet fixed point of the renormalisation group; a fit to a RG-inspired equation of state in the vicinity of the fixed point yields distinct critical exponents for N_f=2 and N_f=4, while no fit is found for N_f=6, suggesting there is a critical number N_fc<6 beyond which no chiral symmetry breaking occurs. The spectrum of the N_f=2 theory is studied; the states examined vary sharply but continuously across the transition.Comment: 50 pages LaTeX, including 16 tables and 20 figures - uses style file ldd_art.sty (included

Couplings of light I=0 scalar mesons to simple operators in the complex plane

The flavour and glue structure of the light scalar mesons in QCD are probed by studying the couplings of the I=0 mesons $\sigma(600)$ and $f_0(980)$ to the operators $\bar{q}q$, $\alpha_s G^2$ and to two photons. The Roy dispersive representation for the $\pi\pi$ amplitude $t_0^0(s)$ is used to determine the pole positions as well as the residues in the complex plane. On the real axis, $t_0^0$ is constrained to solve the Roy equation together with elastic unitarity up to the K\Kbar threshold leading to an improved description of the $f_0(980)$. The problem of using a two-particle threshold as a matching point is discussed. A simple relation is established between the coupling of a scalar meson to an operator $j_S$ and the value of the related pion form-factor computed at the resonance pole. Pion scalar form-factors as well as two-photon partial-wave amplitudes are expressed as coupled-channel Omn\`es dispersive representations. Subtraction constants are constrained by chiral symmetry and experimental data. Comparison of our results for the $\bar{q}q$ couplings with earlier determinations of the analogous couplings of the lightest I=1 and $I=1/2$ scalar mesons are compatible with an assignment of the $\sigma$, $\kappa$, $a_0(980)$, $f_0(980)$ into a nonet. Concerning the gluonic operator $\alpha_s G^2$ we find a significant coupling to both the $\sigma$ and the $f_0(980)$.Comment: 31 pages, 5 figure

Quantum Disordered Regime and Spin Gap in the Cuprate Superconductors

We discuss the crossover from the quantum critical, $z\!=\!1$, to the quantum disordered regime in high-T$_c$ materials in relation to the experimental data on the nuclear relaxation, bulk susceptibility, and inelastic neutron scattering. In our scenario, the spin excitations develop a gap $\Delta\!\sim\!1/\xi$ well above T$_c$, which is supplemented by the quasiparticle gap below T$_c$. The above experiments yield consistent estimates for the value of the spin gap, which increases as the correlation length decreases.Comment: 14 pages, REVTeX v3.0, PostScript file for 3 figures is attached, UIUC-P-93-07-06

Dalitz plot analysis of D_s+ and D+ decay to pi+pi-pi+ using the K-matrix formalism

FOCUS results from Dalitz plot analysis of D_s+ and D+ to pi+pi-pi+ are presented. The K-matrix formalism is applied to charm decays for the first time to fully exploit the already existing knowledge coming from the light-meson spectroscopy experiments. In particular all the measured dynamics of the S-wave pipi scattering, characterized by broad/overlapping resonances and large non-resonant background, can be properly included. This paper studies the extent to which the K-matrix approach is able to reproduce the observed Dalitz plot and thus help us to understand the underlying dynamics. The results are discussed, along with their possible implications on the controversial nature of the sigma meson.Comment: To be submitted to Phys.Lett.B A misprint corrected in formula

Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study

Background We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. Methods We calculated costs and quality-adjusted life-years from the UK National Health Service and Personal Social Services perspective. We performed a within-trial analysis using the efficacy, safety, resource use and health utility data from a randomised controlled trial (LEAVO) over 100 weeks. We built a discrete event simulation to model long-term outcomes. We estimated utilities using the Visual-Functioning Questionnaire-Utility Index, EQ-5D and EQ-5D with an additional vision question. We used standard UK costs sources for 2018/19 and a cost of £28 per bevacizumab injection. We discounted costs and quality-adjusted life-years at 3.5% annually. Results Bevacizumab was the least costly intervention followed by ranibizumab and aflibercept in both the within-trial analysis (bevacizumab: £6292, ranibizumab: £13,014, aflibercept: £14,328) and long-term model (bevacizumab: £18,353, ranibizumab: £30,226, aflibercept: £35,026). Although LEAVO did not demonstrate bevacizumab to be non-inferior for the visual acuity primary outcome, the three interventions generated similar quality-adjusted life-years in both analyses. Bevacizumab was always the most cost-effective intervention at a threshold of £30,000 per quality-adjusted life-year, even using the list price of £243 per injection. Conclusions Wider adoption of bevacizumab for the treatment of macular oedema due to central retinal vein occlusion could result in substantial savings to healthcare systems and deliver similar health-related quality of life. However, patients, funders and ophthalmologists should be fully aware that LEAVO could not demonstrate that bevacizumab is non-inferior to the licensed agents

The Infrared Behaviour of the Pure Yang-Mills Green Functions

We review the infrared properties of the pure Yang-Mills correlators and discuss recent results concerning the two classes of low-momentum solutions for them reported in literature; i.e. decoupling and scaling solutions. We will mainly focuss on the Landau gauge and pay special attention to the results inferred from the analysis of the Dyson-Schwinger equations of the theory and from "{\it quenched}" lattice QCD. The results obtained from properly interplaying both approaches are strongly emphasized.Comment: Final version to be published in FBS (54 pgs., 11 figs., 4 tabs

Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

Background Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to treat macula oedema due to central retinal vein occlusion, but their relative clinical effectiveness, cost-effectiveness and impact on the UK NHS and Personal Social Services have never been directly compared over the typical disease treatment period. Objective The objective was to compare the clinical effectiveness and cost-effectiveness of three intravitreal antivascular endothelial growth factor agents for the management of macula oedema due to central retinal vein occlusion. Design This was a three-arm, double-masked, randomised controlled non-inferiority trial. Setting The trial was set in 44 UK NHS ophthalmology departments, between 2014 and 2018. Participants A total of 463 patients with visual impairment due to macula oedema secondary to central retinal vein occlusion were included in the trial. Interventions The participants were treated with repeated intravitreal injections of ranibizumab (n = 155), aflibercept (n = 154) or bevacizumab (n = 154). Main outcome measures The primary outcome was an increase in the best corrected visual acuity letter score from baseline to 100 weeks in the trial eye. The null hypothesis that aflibercept and bevacizumab are each inferior to ranibizumab was tested with a non-inferiority margin of –5 visual acuity letters over 100 weeks. Secondary outcomes included additional visual acuity, and imaging outcomes, Visual Function Questionnaire-25, EuroQol-5 Dimensions with and without a vision bolt-on, and drug side effects. Cost-effectiveness was estimated using treatment costs and Visual Function Questionnaire-Utility Index to measure quality-adjusted life-years. Results The adjusted mean changes at 100 weeks in the best corrected visual acuity letter scores were as follows – ranibizumab, 12.5 letters (standard deviation 21.1 letters); aflibercept, 15.1 letters (standard deviation 18.7 letters); and bevacizumab, 9.8 letters (standard deviation 21.4 letters). Aflibercept was non-inferior to ranibizumab in the intention-to-treat population (adjusted mean best corrected visual acuity difference 2.23 letters, 95% confidence interval –2.17 to 6.63 letters; p = 0.0006), but not superior. The study was unable to demonstrate that bevacizumab was non-inferior to ranibizumab in the intention-to-treat population (adjusted mean best corrected visual acuity difference –1.73 letters, 95% confidence interval –6.12 to 2.67 letters; p = 0.071). A post hoc analysis was unable to demonstrate that bevacizumab was non-inferior to aflibercept in the intention-to-treat population (adjusted mean best corrected visual acuity difference was –3.96 letters, 95% confidence interval –8.34 to 0.42 letters; p = 0.32). All per-protocol population results were the same. Fewer injections were required with aflibercept (10.0) than with ranibizumab (11.8) (difference in means –1.8, 95% confidence interval –2.9 to –0.8). A post hoc analysis showed that more bevacizumab than aflibercept injections were required (difference in means 1.6, 95% confidence interval 0.5 to 2.7). There were no new safety concerns. The model- and trial-based cost-effectiveness analyses estimated that bevacizumab was the most cost-effective treatment at a threshold of £20,000–30,000 per quality-adjusted life-year. Limitations The comparison of aflibercept and bevacizumab was a post hoc analysis. Conclusion The study showed aflibercept to be non-inferior to ranibizumab. However, the possibility that bevacizumab is worse than ranibizumab and aflibercept by 5 visual acuity letters cannot be ruled out. Bevacizumab is an economically attractive treatment alternative and would lead to substantial cost savings to the NHS and other health-care systems. However, uncertainty about its relative effectiveness should be discussed comprehensively with patients, their representatives and funders before treatment is considered. Future work To obtain extensive patient feedback and discuss with all stakeholders future bevacizumab NHS use. Trial registration Current Controlled Trials ISRCTN13623634. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 38. See the NIHR Journals Library website for further project information

Widths of astrophysically important resonances in 18Ne

The astrophysically important reaction 14O(α,p)17F has been studied through a measurement of the time-inverse p(17F,α)14O reaction using a radioactive 17F beam. Resonance parameters for several states above an excitation energy of 7 MeV in 18Ne have been obtained. Through a measurement of the partial widths for elastic and inelastic proton scattering, it was determined that for these resonances the contribution of the 14O(α,p)17F* branch populating the first excited state in 17F is small. The results indicate that the contribution of resonances above Ex=7 MeV to the astrophysical (α,p) reaction rate is smaller than was previously assumed

Dalitz plot analysis of the D+ to K-pi+pi+ decay in the FOCUS experiment

Using data collected by the high energy photoproduction experiment FOCUS at Fermilab we performed a Dalitz plot analysis of the Cabibbo favored decay D+ to K-pi+ pi+. This study uses 53653 Dalitz-plot events with a signal fraction of ~ 97%, and represents the highest statistics, most complete Dalitz plot analysis for this channel. Results are presented and discussed using two different formalisms. The first is a simple sum of Breit--Wigner functions with freely fitted masses and widths. It is the model traditionally adopted and serves as comparison with the already published analyses. The second uses a K-matrix approach for the dominant S-wave, in which the parameters are fixed by first fitting Kpi scattering data and continued to threshold by Chiral Perturbation Theory. We show that the Dalitz plot distribution for this decay is consistent with the assumption of two body dominance of the final state interactions and the description of these interactions is in agreement with other data on the Kpi final state.Comment: 21 pages, 10 figures, to be submitted to Phys.Lett.